Clinical Advances in Lupus Nephritis
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: closed (25 March 2022) | Viewed by 12090
Special Issue Editor
Interests: glomerulonephritis; vasculitis; lupus nephritis; autoimmunity;
Special Issue Information
Dear Colleagues,
Systemic lupus erythematosus (SLE) is the prototype of autoimmune conditions characterised by an abnormal autoimmune response associated with a loss of tolerance to endogenous nuclear antigens leading to inflammation in various tissues. Lupus nephritis (LN) can occur in up to 60% of patients with SLE and represents a major cause of morbidity and mortality. A growing body of recent insights into the genetic and molecular mechanisms in SLE and LN has triggered the development of novel therapies for these patients. The B-cell-centred approaches have been paralleled by the identification of additional multiple extrarenal and intrarenal pathways contributing to kidney-specific autoimmunity leading to the investigation of novel therapeutic strategies. The formerly induction-maintenance treatment approaches were recently challenged by the promising results obtained from trials that evaluated add-on therapy with voclosporin, belimumab, or obinutuzumab. The scope of this Special Issue is to provide a critical insight into the current knowledge of LN pathogenesis and future therapeutic strategies.
Dr. Roberta Fenoglio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lupus nephritis
- systemic lupus erythematosus
- kidney biopsy, B-cells
- rituximab
- obinutuzumab
- anifrolumab
- belimumab
- interferon
- neutrophils
- pathogenesis
- voclosporin
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.